文献速递慢性肾脏病

镰状细胞病患者估算肾小球滤过率进行性下降:一项观察性队列研究

Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2019-02-21

本研究为单中心回顾性观察性研究,纳入2004至2013年427例成人镰状细胞病患者,评估慢性肾脏病(CKD)患病率及估算肾小球滤过率(eGFR)下降情况。中位随访4.01年,严重基因型患者eGFR年下降2.05 mL/min/1.73m²,轻度基因型下降1.16 mL/min/1.73m²,eGFR下降与疾病严重程度标志物相关。

要点

  • 镰状细胞病患者eGFR随时间快速下降,严重基因型下降更显著。
  • 基线CKD在严重基因型中占21.4%,轻度基因型中占17.2%。
  • 严重基因型中ACEI/ARB使用与基线CKD正相关,血红蛋白水平与eGFR下降速率负相关。

核心结论

  • 镰状细胞病患者eGFR随时间快速下降,下降速率与疾病严重程度标志物及相关合并症相关。

研究设计与样本

  • 回顾性观察性研究,单中心2004至2013年纳入427例18岁及以上镰状细胞病患者,其中331例有至少2次肌酐测量。

主要发现

  • 中位随访4.01年(四分位距1.66-7.19),严重基因型eGFR年下降2.05 mL/min/1.73m²(P<0.001),轻度基因型年下降1.16 mL/min/1.73m²(P=0.02)。
  • 基线时严重基因型CKD患病率为21.4%,轻度基因型为17.2%。
  • 严重基因型中,ACEI/ARB使用与基线CKD相关(OR 6.10,95%CI 2.03-18.29,P=0.001),股骨头坏死与基线CKD相关(OR 0.40,95%CI 0.16-0.97,P=0.04)。
  • 轻度基因型中,血红蛋白每升高1 g/dL,CKD概率降低(OR 0.63,95%CI 0.43-0.93,P=0.02)。
  • 严重基因型亚组中,eGFR下降速率与血红蛋白水平呈负相关(β=0.46,SE=0.23,P=0.04)。

临床怎么用

  • 对镰状细胞病患者应监测eGFR变化,尤其是严重基因型患者。
  • 血红蛋白水平可能有助于识别CKD风险较高的患者。

局限性

  • 回顾性观察性研究,白蛋白尿直接测量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Progression of chronic kidney disease (CKD) in sickle cell disease (SCD) and its risk factors remain poorly defined. We identified characteristics associated with CKD as well as decline in estimated glomerular filtration rate (eGFR) and presence of proteinuria over time in adults with SCD. STUDY DESIGN: Retrospective observational study. SETTING & PARTICIPANTS: Patients with SCD 18 years or older in a single center from 2004 to 2013. PREDICTORS: Baseline clinical and laboratory measures, comorbid conditions, SCD-related complications, relevant treatments, and severity of genotypes defined as severe (homozygous SCD [HbSS]/sickle-β0-thalassemia [HbSβ0]) or mild (hemoglobin SC disease [HbSC]/sickle-β+-thalassemia [HbSβ+]-thalassemia). OUTCOMES: Presence at baseline of CKD, defined here as eGFR<90mL/min/1.73m2 or proteinuria (≥1+) on urinalysis or current kidney transplant or dialysis therapy; change in eGFR; and presence of proteinuria over time. ANALYTICAL APPROACH: Logistic regression for baseline CKD. Linear mixed-effects model for eGFR decline and generalized linear mixed-effects model for proteinuria during the study period evaluating for interaction with time. Stratified by genotype severity. RESULTS: Among 427 patients, 331 had 2 or more measurements of creatinine. During a median follow-up of 4.01 (interquartile range, 1.66-7.19) years, annual eGFR decline was 2.05mL/min/1.73m2 for severe genotypes (P<0.001) and 1.16mL/min/1.73m2 (P=0.02) for mild genotypes. At baseline, 21.4% of patients with severe genotypes had CKD versus 17.2% of those with mild genotypes. For severe genotypes, angiotensin-converting enzyme-inhibitor/angiotensin receptor blocker use (OR, 6.10; 95% CI, 2.03-18.29; P=0.001) and avascular necrosis (OR, 0.40; 95% CI, 0.16-0.97; P=0.04) were associated with baseline CKD. Among those with mild genotypes, higher hemoglobin level was associated with lower probability of CKD (OR per 1-g/dL greater hemoglobin level, 0.63; 95% CI, 0.43-0.93; P=0.02). Rate of eGFR decline was inversely related to hemoglobin level (β = 0.46 [SE, 0.23]; P=0.04) within the severe genotype subgroup. No factors were identified to be associated with proteinuria over time. LIMITATIONS: Retrospective observational study, limited direct measures of albuminuria. CONCLUSIONS: Patients with SCD exhibit rapid decline in eGFR over time. Decline in eGFR is associated with markers of disease severity and associated comorbid conditions.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Derebail VK, Ciccone EJ, Zhou Q, et al. Progressive Decline in Estimated GFR in Patients With Sickle Cell Disease: An Observational Cohort Study. Am J Kidney Dis. 2019. PMID: 30797615. doi:10.1053/j.ajkd.2018.12.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。